- Sites Globally
Improve Human Health by Innovation
Unleash the power of oligonucleotide therapeutics to tackle unmet medical needs.
Our Core Values
Integrity & Decency • Innovation & Persistence • Diligence & Perfection
Ractigen /răk’tijən/: RNA activates genes.
Ractigen Therapeutics is an early-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells.
Ractigen Therapeutics was founded in 2017 by the original pioneers in the field of RNAa to create a pipeline of new medicines to treat diseases caused by insufficient gene expression.
Our core technology is based on a discovery made at the University of California San Francisco (UCSF) coined RNA activation (RNAa) that prompted a paradigm shift in the field of oligonucleotides therapeutics – targeted activation of gene expression using short non-coding RNA duplexes.
Our headquarters occupies a four-storied building in the Modern Industry Park of Life and Health Science of Rudong, Jiangsu, China.
We also occupy a growing laboratory space in the Zhangjiang High Technology Park in Shanghai, and have a 2000 sq. m. R&D center in the BioBay in Suzhou.
Our company is also launching our first international venture with a US site that is under construction within the Washington DC area.
Ractigen is led by a cohesive team of scientists, professionals, and biotech entrepreneurs with broad backgrounds in oligonucleotide research, chemistry, and drug development including the original core team of inventors behind the RNAa technology.